Clinical Trial Update: A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 dose-response study evaluating oral AP1189 in DMARD-naïve patients with early rheumatoid arthritis. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AP1189

Snippet

Sponsor: SynAct Pharma Aps | Conditions: Rheumatoid Arthritis (RA) | Phase 2 | Status: RECRUITING